Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Smallest Microscope Views Live Tissue in Real Time

By LabMedica International staff writers
Posted on 03 Feb 2010
The world's smallest flexible microscope is diagnosing cancer and other deadly diseases, allowing physicians to treat patients on the spot. More...


Dr. Michel Kahaleh, associate professor of medicine in the division of gastroenterology and hepatology at the University of Virginia Health System (Charlottesville, USA), is utilizing the new technology, called probe-based confocal laser endomicroscopy (pCLE). pCLE is a technique that allows the user to view live tissue in real time at the cellular level. This allows the identification of cancer with pinpoint precision and permits precise removal of the diseased tissue.

"Until now, if we found suspicious tissue during one of these diagnostic procedures, we often had to randomly sample it and send it to the laboratory for analysis, which can take up to a week,” said Dr. Kahaleh. "With pCLE, we can pinpoint the dangerous tissue during the initial diagnostic procedure and remove or treat it the same day.”

Dr. Kahaleh and his team are using pCLE to effectively distinguish cancerous and precancerous tissue during colonoscopies, upper endoscopies, and the conventional pancreatic and bile duct cancer detection procedure. They are also using pCLE to find and treat gastrointestinal cancers and other gastrointestinal (GI) diseases, including those of the colon, bile duct, pancreas, and esophagus. "This new imaging tool gives us the opportunity to immediately see changes up to the cell level and potentially gain insights of what may be wrong, thus optimizing patient treatment,” Dr. Kahaleh explained.

Dr. Kahaleh also believes that this technique represents the future of medicine a future in which doctors and researchers deliver ways to diagnose and treat diseases all at once. He thinks this will save time and reduce trauma for patients while improving efficiency.

Cellvizio is the technology platform that enables the pCLE technique. It was cleared by the U.S. Food & Drug Administration (FDA) for use in the gastrointestinal tract and lungs, and over 5,000 Cellvizio procedures have been completed worldwide to date. The technology was developed by Mauna Kea Technologies (Paris, France).

Related Links:
University of Virginia Health System
Mauna Kea Technologies


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic Hematology Analyzer
DH-800 Series
New
Silver Member
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.